• LAST PRICE
    1.1400
  • TODAY'S CHANGE (%)
    Trending Down-0.0200 (-1.7241%)
  • Bid / Lots
    1.1200/ 5
  • Ask / Lots
    1.2500/ 1
  • Open / Previous Close
    1.1400 / 1.1600
  • Day Range
    Low 1.1200
    High 1.1500
  • 52 Week Range
    Low 1.0308
    High 2.3600
  • Volume
    260,806
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.16
TimeVolumePLX
09:32 ET16161.14
09:34 ET6851.145
09:38 ET1001.145
09:41 ET248491.13
09:45 ET114381.12
09:48 ET2001.125
09:50 ET55141.1299
09:52 ET3001.14
09:57 ET1001.1305
10:03 ET1001.1305
10:06 ET35301.13
10:10 ET1001.12
10:12 ET2881.1296
10:14 ET104181.12
10:19 ET1001.125
10:24 ET9071.12
10:26 ET1001.13
10:28 ET7191.125
10:30 ET19001.13
10:33 ET1001.14
10:35 ET7001.14
10:42 ET2001.13
10:50 ET11961.1399
10:51 ET1001.131
10:55 ET1001.14
11:00 ET1821.13
11:06 ET44001.14
11:08 ET15451.135
11:11 ET2001.135
11:13 ET6001.14
11:18 ET16991.135
11:22 ET1001.14
11:24 ET11001.14
11:29 ET19311.1315
11:31 ET2001.14
11:36 ET3001.14
11:38 ET8001.14
11:40 ET2001.1375
11:42 ET1031.14
11:44 ET8001.14
11:45 ET7001.14
11:47 ET2001.14
11:49 ET2011.1325
11:51 ET7001.14
11:54 ET5361.14
11:56 ET5001.135
11:58 ET168501.14
12:02 ET1001.14
12:03 ET1001.14
12:05 ET28001.1375
12:09 ET1001.14
12:14 ET1001.135
12:18 ET5641.135
12:23 ET10001.1399
12:25 ET3001.14
12:27 ET1001.14
12:30 ET3001.14
12:32 ET6001.14
12:34 ET2051.14
12:38 ET4061.14
12:41 ET9061.135
12:43 ET7391.14
12:45 ET34701.135
12:48 ET6281.14
12:50 ET4001.1375
12:52 ET21011.1399
12:54 ET33001.1375
12:56 ET1001.14
12:57 ET7771.14
12:59 ET1001.14
01:01 ET1001.1375
01:03 ET1001.135
01:06 ET23821.14
01:15 ET1001.13
01:17 ET6351.14
01:32 ET1001.1375
01:37 ET1001.14
01:39 ET2001.14
01:42 ET3001.14
01:44 ET4001.14
01:46 ET5351.135
01:51 ET17771.1375
01:55 ET1031.14
01:57 ET3011.14
02:00 ET4001.14
02:02 ET5001.14
02:06 ET12501.14
02:08 ET11001.1398
02:09 ET6501.135
02:11 ET1001.135
02:13 ET15661.135
02:15 ET1001.135
02:18 ET10081.14
02:22 ET3001.1375
02:27 ET2001.14
02:29 ET4061.135
02:31 ET3071.1375
02:33 ET1001.14
02:36 ET4021.14
02:38 ET3451.1356
02:40 ET2001.14
02:42 ET5371.135
02:44 ET2011.14
02:45 ET2071.14
02:49 ET1481.14
02:51 ET1001.1375
02:58 ET1481.1388
03:02 ET1001.1375
03:03 ET1001.135
03:05 ET6351.14
03:09 ET1001.1375
03:12 ET1361.135
03:14 ET2001.135
03:16 ET2001.135
03:18 ET1041.14
03:20 ET1001.1375
03:23 ET2051.1375
03:25 ET6821.1314
03:27 ET36881.135
03:30 ET5171.14
03:32 ET1001.14
03:34 ET3571.135
03:36 ET5571.14
03:38 ET1001.14
03:39 ET4001.1325
03:41 ET76111.14
03:43 ET30071.14
03:45 ET5001.14
03:48 ET13881.14
03:50 ET13111.145
03:52 ET13481.15
03:54 ET5001.15
03:56 ET19001.15
03:57 ET18261.14
03:59 ET500471.14
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPLX
Protalix Biotherapeutics Inc
83.6M
18.8x
---
United StatesCDTX
Cidara Therapeutics Inc
61.3M
-1.7x
---
United StatesBIOQ
Bioqual Inc
64.8M
67.8x
-25.28%
United StatesMDXH
MDxHealth SA
76.7M
-2.5x
---
United StatesPSNL
Personalis Inc
70.6M
-0.7x
---
United StatesCSBR
Champions Oncology Inc
68.4M
-7.0x
---
As of 2024-06-16

Company Information

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

Contact Information

Headquarters
2 University Plaza, Suite 100HACKENSACK, NJ, United States 07601
Phone
201-696-9345
Fax
845-818-3588

Executives

Independent Chairman of the Board
Eliot Forster
President, Chief Executive Officer, Director
Dror Bashan
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Eyal Rubin
Senior Vice President - Operations
Yaron Naos
Independent Director
Amos Bar Shalev

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$83.6M
Revenue (TTM)
$59.7M
Shares Outstanding
73.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.78
EPS
$0.06
Book Value
$0.46
P/E Ratio
18.8x
Price/Sales (TTM)
1.4
Price/Cash Flow (TTM)
10.3x
Operating Margin
13.52%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.